Physician profile
Mark A Fierro
NPI 1114155496
$12,836.69
in general payments reported to CMS, 2019-2025
42 companies · $2,378 in 2025
The $2,378 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $1,065 · 2021: $1,588 · 2022: $2,555 · 2023: $1,976 · 2024: $2,230 · 2025: $2,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,583.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $2,180.42 | 2020-2025 | Aplenzin, Wellbutrin |
| Abbvie INC. | $2,025.46 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $1,019.80 | 2021-2025 | |
| Myovant Sciences INC. | $843.53 | 2021-2022 | |
| Astellas Pharma US INC | $775.98 | 2020-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $771.21 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $704.69 | 2019-2025 | Trintellix |
| Therapeuticsmd, INC. | $559.59 | 2019-2022 | |
| Amgen INC. | $549.26 | 2019-2025 | Evenity, Prolia, Prolia |
| Biohaven Pharmaceutical Holding Company Ltd. | $302.38 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $297.35 | 2020-2021 | |
| Roche Diagnostics Corporation | $244.81 | 2019-2021 | |
| Eisai INC. | $224.46 | 2020-2022 | |
| Avion Pharmaceuticals | $190.76 | 2019-2022 | |
| Lilly USA, LLC | $189.16 | 2019-2025 | Zepbound |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $164.26 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $152.99 | 2019-2023 | Belsomra, Bridion |
| Terumo Medical Corporation | $137.93 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $134.40 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $132.20 | 2019 | |
| Sumitomo Pharma America, INC. | $122.44 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $115.25 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Amag Pharmaceuticals, INC. | $93.12 | 2019-2020 | |
| Lundbeck LLC | $90.97 | 2024 | Rexulti |
| Novo Nordisk INC | $80.09 | 2023-2024 | Wegovy |
| Allergan, INC. | $75.73 | 2019-2020 | |
| Ascend Therapeutics US, LLC | $73.10 | 2020-2022 | |
| Exeltis, USA INC. | $69.38 | 2019-2021 | |
| Hologic Sales and Service, LLC | $61.55 | 2019-2025 | Acessa Provu System, Myosure Tissue Removal Device, Novasure |
| Idorsia Pharmaceuticals US INC | $58.87 | 2022-2024 | Quviviq |
| Mission Pharmacal Company | $51.17 | 2019 | |
| Exact Sciences Corporation | $49.53 | 2025 | Cologuard Collection Kit |
| Zyla Life Sciences, INC. | $38.32 | 2020 | |
| Ethicon US, LLC | $38.28 | 2022 | |
| Avanos Medical | $35.53 | 2025 | On-Q Pump and Accessories |
| Baxter Healthcare | $35.29 | 2025 | Perclot |
| Ibsa Pharma INC. | $34.61 | 2020 | |
| Meditrina | $34.52 | 2024-2025 | |
| Becton, Dickinson and Company | $20.85 | 2020 | |
| Lupin INC. | $20.78 | 2019 | |
| Aspira Women'S Health INC | $19.22 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.45 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fierro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.